About Our Company

Biological Dynamics is a private molecular diagnostics company located in San Diego. Founded in 2010, based on innovation developed at UC San Diego’s Jacobs School of Engineering, the company is pursuing the use of ACE technology to improve detection, treatment and monitoring of cancers.  Biological Dynamics first product, the OncoState™ Lung assay, will utilize the platform to support treatment response in for patients with Non-Small Cell Lung Cancer.

Raj Krishnan, PhD - CEO

Dr. Raj Krishnan founded Biological Dynamics in 2010 with the mission to revolutionize the approach toward the diagnosis and treatment of high burden diseases – the manifestation of his long desire to help people with cancer and save lives. Receiving his Ph.D. in Bioengineering from UC San Diego, Raj moved to build a company based on the technology he developed for his dissertation, where he pioneered the use of AC Electrokinetics for the purpose of blood-based diagnosis.

For the past several years, under Raj's vision and guidance, Biological Dynamics has transformed from concept to early stage startup, and then to one of the most innovative diagnostic companies in Southern California. His passion and conviction has led Biological Dynamics through three rounds of funding, securing over $50 million in total. Raj has published several papers on AC Electrokinetics and was named to the Top 30 under 30 scientists by Forbes magazine.

Richard Slansky, CFO

Richard joined Biological Dynamics in November 2018. Richard is a seasoned executive with a respected financial and operational leadership style. He has an extensive background and breadth of experience in both public and private commercial healthcare and high technology organizations. He has a successful track record developing innovative solutions, building team consensus to drive results, and raising substantial development and operational funds in the public market.

Prior to joining Biological Dynamics, Richard was chief financial officer of OncoSec Medical, Inc., a public immuno-oncology company where he helped raise funding in the public market, interfaced with investors and analysts, lead the back-office functions of accounting, finance, human resources, information technology, and corporate communications. Prior to OncoSec, Richard was chief financial officer of GenMark Diagnostics, Inc., and has held several leadership positions with early stage San Diego based companies. Richard also holds board positions with public and private companies. He earned his bachelor’s degree from the Wharton School at the University of Pennsylvania and his MBA from the Eller Graduate School of Management at the University of Arizona.

Scott Conradson, SVP, R&D

Scott has been engaged with Biological Dynamics since February 2016. Scott has over 24 years of experience in executive R&D and business management positions with P&L responsibility at diagnostic and life science startups and Fortune 1000 companies, including Life Technologies, Bio-Rad, and Hewlett-Packard. He has led teams in the development, marketing, and support of platform, application, and services products such as transplant (HLA) DNA and antibody assays, DNA sequencers from Sanger through nanopores, protein profiling using MALDI mass spectrometers, flow cytometry, and DNA arrays.

Scott received his master’s degree in electrical engineering from Santa Clara University and his bachelor’s degree in mechanical engineering from Cal Poly San Luis Obispo with additional work at UCLA in biochemistry and graduate work at Stanford. Scott has attended executive business programs at Northwestern University and the University of California at Berkeley. In addition, he has been an invited speaker at IVD and engineering conferences worldwide, and currently holds seven patents with several pending in areas ranging from protein identification using charge detection to artificial intelligence applied to computer-aided engineering systems.

Iryna Clark, Sr. Director, Commercial Operations

Iryna joined Biological Dynamics in November 2014. Iryna leads the development of business processes that support the entire spectrum of Biological Dynamics’ commercial operations, including market development, market access (reimbursement and evidence development activities), product positioning, pricing, field operations, and sales support. Iryna brings to Biological Dynamics a strong, multidimensional background with over 20 years of experience across multiple disciplines, including over 14 years of leadership experience in Life Sciences.

Prior to joining Biological Dynamics, Iryna advised small- and medium-sized businesses in the Life Sciences, Venture Capital, and Technology verticals, guiding commercial operations in regulated markets, as well as leading initiatives in strategic market and product development, product positioning, competitive research, and go-to-market strategy. Prior to her advisory role, Iryna was the Director of Marketing at Innovive, Inc. (San Diego, CA), where she led the global commercial launch and growth strategy for a novel, high-tech suite of products intended for Laboratory Animal Science/Medical Research markets. Iryna holds an MBA from UCLA Anderson School of Management, as well as a bachelor’s degree in fine arts from the University of California, San Diego. In addition, she holds a bachelor’s degree in nursing from Sumy Medical College in Sumy, Ukraine.

Juan Pablo “JP” Hinestrosa, Ph.D., Sr. Director, Research

JP joined Biological Dynamics in March 2013.  JP leads the research team in their efforts to develop the Verita™ platform, including the discovery of new applications and biomarkers implementing AC Electrokinetics.  JP has been instrumental in the development Biological Dynamics’ biochip, drastically improving its efficiency and performance. In addition, he has demonstrated the capability of AC Electrokinetics to identify cell-free DNA, exosomes, RNA, and proteins.

Prior to joining Biological Dynamics, JP completed postdoctoral assignments for the United States Department of Energy’s Oak Ridge National Laboratory and the École Polytechnique Fédérale de Lausanne in Switzerland, where he focused on the integration of chemistry, biology, and materials science for the generation of biochips. JP has authored numerous publications in the fields of biocompatible surfaces, nanofabrication, and self-assembled polymers. He holds a Ph.D. in chemical & biomolecular engineering from Clemson University as well as a bachelor’s degree in chemical engineering from Universidad Del Valle (Cali, Colombia).

Rob Turner, Sr. Director, Product Development

Rob joined Biological Dynamics in March 2011. Rob leads the product development team in the engineering, design, and development of Biological Dynamics’ products – including IVD instrumentation hardware, software, and consumable design, development, and manufacturing, industrial design, and usability engineering. Rob has led the design and development of numerous devices implementing AC Electrokinetics technology, most notably the NanoVerita™ – Biological Dynamics’ first CE marked instrument, the OmniVerita™ – a benchtop treatment response monitoring device, and the OmniVerita™ M – a smartphone enabled portable device intended for cancer detection and infectious disease diagnostics.

Rob holds two patents with several pending in areas including the implementation of AC Electrokinetics for isolating nucleic acids, the design of non-biohazardous consumables, and the integration of smartphones with AC electrokinetics. He earned his master’s degree in bioengineering and bachelor’s degree in bioengineering from the University of California, San Diego.

Robert Kovelman, Ph.D., Sr. Director, Assay Development and Clinical Affairs

Robert joined Biological Dynamics in July 2016. Robert leads the team that develops assays on the Verita™ platform, as well as other molecular and biochemical assays that support Biological Dynamics’ development efforts. Robert also has responsibility for Clinical Affairs, including the management of collaborative partnerships that support the company’s research and clinical trials, and the company’s regulatory strategy for obtaining IVD clearance. Robert has been key in the demonstration of analytical and clinical feasibility of the company’s novel AC Electrokinetic assays, the development of prototype assays for obtaining regulatory clearance, and the advancement of the company’s regulatory strategy for obtaining de novo clearance of the assay and instrument.

Prior to joining Biological Dynamics, Robert was senior director of R&D for the transplant diagnostics division at Thermo Fisher Scientific, where he led teams developing US FDA 510(k)-cleared and CE-marked molecular typing products and immunodiagnostics. Robert has held additional roles leading teams that developed life science tools and technologies at EMD Millipore (now Millipore Sigma) and groups performing drug discovery at Signal Pharmaceuticals (now Celgene). Robert earned a bachelor’s degree in biochemistry at Columbia University, and his Ph.D. in biochemistry and molecular biology at The Rockefeller University. He has also had subsequent training as a postdoctoral research associate at The Scripps Research Institute.

David Liu, Ph.D., Director, Quality Assurance

David joined Biological Dynamics in May 2012. David started his career at Biological Dynamics as a polymer chemist researching and developing AC Electrokinetics. David then transitioned to Quality, establishing the Quality department in 2014. He implemented Biological Dynamics’ Quality Management System compliance to US FDA and European regulations. David led the effort to ensure success with external audits in obtaining ISO 13485 certification and subsequent surveillance audits for Biological Dynamics. Additionally, in collaboration with the product development team, David completed the technical file for the NanoVerita – Biological Dynamics’ CE marked instrument.

Prior to joining Biological Dynamics, David was a research associate at The City College of New York working on flexible and modular energy storage devices. David holds a Ph.D. in Chemistry from University of Florida, and a bachelor’s degree in chemistry from the University of North Carolina at Chapel Hill.